Facilitating Access to Approved Medication

Artesunate Injection 60 mg
Artesunate injection is used to treat severe malaria. This medicine is also used together with other medicines (eg, 8-aminoquinoline medicine) to treat severe malaria caused by Plasmodium ovale or Plasmodium vivax. Artesunate belongs to a group of medicines known as antimalarials.

Get Access To Artesunate Injection 60 mg

Artesunate injection is under study for the treatment of cancer and COVID 19.
In 2007, the FDA approved an Investigational New Drug (IND) protocol for intravenous artesunate.

Artesunate Injection Available Price In India UK Saudi Arabia

 Artesunate Injection

  • Generic Brand Name – On Request
  • API – Artesunate
  • Packaging – Single-Use Vial
  • Strength – 60mg
  • Manufacturer Name – Zydus Cadila

What is artesunate used for?

ARTESUNATE Injection is an artemisinin derivative prescribed for the treatment of malaria. As an intravenous form, it is preferred to quinine for the severe malaria. Often it is prescribed as part of combination therapy together with mefloquine. The artesunate uses are not recommended for the prevention of malaria.


    All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.

    Get Access To Artesunate Injection 60 mg

    Shreyaansh Lifesciences, Jaipur. India

    Shreyaansh Lifesciences is registered in Jaipur, India. Registration Number : 08AEEFS9350K1ZI under GST Act. 
    Branch Offices in India : Jaipur | New Delhi

    SF-72-73 2ND FLOOR, Jaipur Electronic Market, Ridhi Sidhi Choraha, Jaipur, Rajasthan, 302018.

    +91 99292 77766

    Facts of Medicines

    Artesunate Injection 60 mg


    Care should be exercised in the handling of ARTESUNATE. ARTESUNATE injections should not be opened or crushed. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze it and avoid exposure to heat. Keep protected from the light. Avoid using beyond the expiration date.


    Artesunate Injection can be administered by intravenous injection or by intramuscular by a healthcare professional. Kindly do not self administer. It is prescribed in cases where an oral administration is not appropriate.
    In case you miss artesunate injection dosage, please consult your healthcare practitioner.


    Most common adverse reactions include body ache, headache, bradycardia, abdominal pain, nausea, dizziness, vomiting, and diarrhoea.


    • Care should be implemented in those patients who are with the hepatic impairment due to the potential hepatotoxic effects.
    • Patients should be monitored for 4 weeks following treatment with the inj falcigo for the evidence of hemolytic anemia.
    • In order to delay the treatment of severe malaria during pregnancy may be responsible for serious morbidity and mortality to the mother as well as fetus.
    • Patients should be advised of the need to complete the appropriate oral antimalarial therapy following treatment with artesunate 120 mg injection.
    • Patients should be instructed of the need for the regular blood tests for the 4-week period after completion of treatment in order to monitor for the post-treatment delayed hemolysis.
    • It is advised that the renal function, glucose, hepatic/haematological function is monitored throughout the treatment.
    • Patients should be monitored for signs of toxicity such as neurological symptoms, persistent vomiting/rash.
      Women with falcigo 120 mg should discuss with their healthcare provider prior to starting breastfeeding and conceiving a baby.

      FAQs – Medicine Questions

      Artesunate Injection 60 mg
      Is Artesunate an antimalarial drug?

      Yes, Artesunate is an antimalarial drug. It is used in the treatment of severe malaria.

      From which class of drug Artesunate belongs?

      The artesunate 60 mg belongs to the class of drugs named artemisinin.

      What are the ingredients of the medicine Artesunate?

      The active ingredient in the medicine is Artesunate, and the inactive ingredients are sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous in water for injection.

      Where can I buy Artesunate injection?

      You can buy Artesunate injection from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

      The buyer should check the existing law in their home country before importing the product.

      What is the procedure to buy Artesunate Injection?

      Patients can simply fill the order form or can send mail at info@treatmentoptions4u.com. Patients can also send WhatsApp messages to +91 99292 77766 / 98738 10020   We will reply ASAP with the details of the Artesunate Injection price as well as procurement procedure.

      Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

      What are commonly reported side effects of Artesunate?

      The acute kidney failure requiring dialysis, yellowing of the skin as well as eyes and hemoglobin in the urine are the commonly reported artesunate side effects.


      1. KD Tripathi, Essentials of Medical Pharmacology, Antimalarial drugs, 7th edition, 2013, 829-831.
      2. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Chemotherapy of malaria, 12th edition, 2011, 1396.
      3. Amivas LLC, US Food and Drug Administration, [Revised on May 2020] [ Accessed on 20th August 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf
      4. Guilin Pharmaceutical Co., Ltd, World Health Organisation Public Assessment Reports (WHOPAR), [Revised on Jan 2020] [ Accessed on 20th August 2021], https://extranet.who.int/pqweb/sites/default/files/MA089part3.pdf